Ocular Therapeutix (NSDQ:OCUL) said today that it inked a deal with an investor to issue $37.5 million in 6% subordinated convertible notes due 2026. The offering is slated to close on March 1, according to the Bedford, Mass.-based company.
Ocular expects to reel in roughly $37.1 million in net proceeds from the offering, which it plans to use to fund the launch of Dextenza and support its late-stage pipeline.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix inks $38m debt financing deal appeared first on MassDevice.
from MassDevice https://ift.tt/2U1y7IB
Cap comentari:
Publica un comentari a l'entrada